Quarterly ResultMay 11, 2026, 04:22 PM
Coherus Oncology Q1 Net Loss $36.9M; LOQTORZI Revenue $11.8M
AI Summary
Coherus Oncology reported a net loss from continuing operations of $36.9 million, or $(0.27) per share, for Q1 2026, an improvement from a $47.4 million loss in Q1 2025. LOQTORZI net revenue increased 61% year-over-year to $11.8 million, despite a 5% sequential decrease attributed to weather and seasonality. The company also completed patient accrual for its 1L HCC Phase 2 trial for casdozokitug and advanced its tagmokitug program, with multiple data readouts expected in 2026.
Key Highlights
- Q1 2026 net loss from continuing operations was $36.9 million, or $(0.27) per diluted share.
- LOQTORZI net revenue reached $11.8 million in Q1 2026, up 61% from Q1 2025.
- Net revenue from continuing operations was $12.3 million in Q1 2026, up from $7.6 million in Q1 2025.
- R&D expenses decreased to $21.5 million in Q1 2026 from $24.4 million in Q1 2025.
- SG&A expenses decreased to $23.1 million in Q1 2026 from $26.0 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $167.0 million as of March 31, 2026.
- Completed patient accrual for 1L HCC Phase 2 trial of casdozokitug, with data expected mid-2026.
- Raised $53.6 million net proceeds from a public offering of common stock in Q1 2026.
Price Impact
More from CHRS